Rampart Bioscience is at the forefront of developing innovative gene medicines that prioritize safety, effectiveness, and accessibility. The company is leveraging its proprietary HALO platform, which is designed to create non-viral DNA-based therapies that address the limitations of traditional gene therapies. This platform enables the production of highly potent, durable, and redosable treatments, specifically targeting genetically driven diseases. Rampart's lead program focuses on hypophosphatasia (HPP), a rare genetic disorder that impedes bone mineralization, showcasing the company's commitment to addressing high-need applications in genetic medicine.

The technology behind Rampart's approach integrates insights from various scientific disciplines, including gene delivery and protein sciences, to enhance therapeutic expression and patient outcomes. By incorporating novel structural elements that facilitate nuclear trafficking and retention while minimizing immune responses, Rampart aims to overcome significant challenges related to potency and durability in gene therapies. The company's multidisciplinary team, with extensive experience in biotechnology and gene therapy, is dedicated to reshaping the treatment landscape for patients, ensuring that their innovative solutions are both effective and accessible.

United States

Rampart Bioscience is evolving a new class of medicines for patients with genetically driven diseases. They integrate capabilities from a variety of key sources to develop gene medicines to provide long-lasting treatments for a wide range of diseases.

Rampart Bioscience

Company Details